Interventional radiologic procedures such as percutaneous transluminal angioplasty and stenting are standard treatment modalities for lesions that affect the lower limb arterial tree. Typically, the lesion is accessed via the transfemoral route, and insertion of sheaths is a routine component of these procedures. Moderate or large hematomas have been reported in up to 4% of hospitalized patients after femoral catheterization [1] , and, therefore, postprocedure removal of these sheaths still poses risks as well as time constraints on the physician.
It is remarkable that almost a half century since the introduction of the Seldinger technique, manual compression still remains the criterion standard for achieving hemostasis after gaining vascular access for diagnostic and interventional arterial catheterization. Increasing time pressure, issues of patient satisfaction, and the use of large-diameter catheters for endovascular intervention, however, have recently necessitated alternative ways of establishing poste endovascular procedure hemostasis.
Since the early 1990s, various devices have been used to achieve hemostasis after arterial puncture. These hemostatic devices can be categorized into 3 main types according to their mechanism of action: pressure devices (CompressAR System; Femostop; RADI Medical Systems, Wilmington, MA), topical hemostatic pads, and vascular closure devices.
The method of achieving hemostasis after arterial catheterization currently varies among and within institutions, and there is currently no best practice recommendation for this.
The CompressAR System was the first mechanical compression device ever to replace manual compression for postcatheterization femoral hemostasis. A newer version of the CompressAR System, the CompressAR StrongArm (UK Medical, Sheffield, United Kingdom), was introduced in 2002. The CompressAR StrongArm is a similar C-clamp compression device to its predecessor, which comprises a nondisposable stand ( Figure 1 ) on which a single disposable sterile disc is used to provide vascular compression for purposes of achieving femoral hemostasis. This latest version has a more durable connection to the arm for reliable femoral compression; a ''sure-grip'' elastomeric material on the undersurface to increase patient comfort and reduce chance of distal disc migration; and a ''V-shaped notch'' on the sterile disc ( Figure 2 ), which enables proper visualization and facilitates cleaning of the puncture site.
In this article, we report the findings of the first prospective audit aimed at evaluating the use of the Com-pressAR StrongArm mechanical compression device in establishing hemostasis after transfemoral angioplasty in the interventional radiology day-case setting.
Methods
The audit sample consisted of 81 consecutive adult patients undergoing elective day-case lower limb angioplasty (with or without stenting) via a transfemoral approach. The CompressAR StrongArm device was used to provide mechanical compression for hemostasis in 84 puncture sites in these patients. Staff at the interventional day-case unit had formal in-house training on the procedure for applying the clamp. Representatives from the manufacturer were responsible for assessing and maintaining staff competence in the use of the compression device.
Informed patient consent was obtained by the attending interventional radiologist before the catheterization procedure for the procedure itself and for the audit. In line with our institutional policy with regard to audits of established practice, approval for this study was obtained from the Radiology Departmental Audit Committee. In all patients, the time taken from subcutaneous administration of local anaesthetic (lidocaine 1%) to successful needle cannulation of the femoral artery was less than 5 minutes. All patients were catheterized with 4F-6F vascular sheaths. All patients received 3000 IU intra-arterial heparin during their elective procedure.
A standard procedure was developed for application of the device to ensure uniformity of use. To decrease variability in sheath removal, the radiologist carrying out the vascular intervention removed the sheaths and deployed the device. The base of the clamp was positioned between the mattress and the base of the patient's bed. The arm was moved into position in relation to the puncture site by rotation of the shaft. The CompressAR disc was attached to a movable slide on the horizontal support arm of the stand. This was then lowered onto the femoral artery immediately proximal and medial to the puncture site, with the sheath located in the V-notch of the disc. The sheath was withdrawn as downward pressure was simultaneously applied to the site. The horizontal support arm was adjusted to exert firm pressure until there was no further visible bleeding at the site, without causing a visible hematoma or compromising distal arterial blood flow. Firm pressure was applied for an initial period (manufacturer recommendation of 5 or 6 minutes), depending on the size of the patient and the sheath size used. Pressure was applied until the bleeding stopped and the disc was seen to indent the skin around the puncture site. Once adequate pressure was achieved, the device was locked in place and released in a stepwise fashion by using a ratchet mechanism at the appropriate time. The amount of pressure applied had a subjective element, just as with hand compression. After deployment, specialist nurses were charged with monitoring the vascular access site and gradually releasing compression until hemostasis was achieved. If, after complete release, there was continued bleeding, the nurse notified the radiologist, and the device was redeployed in accordance with manufacturer's recommendations.
The patients were monitored in a dedicated recovery area within the radiology department. The specialist nurse remained at the patient's bedside for the entire duration of the procedure. All patients received postprocedural instructions from the radiologist who had removed the sheath and also from the nurse. Groin sites were inspected by the nursing staff at the time of sheath removal, at 1 hour, and at 4 hours after the procedure. The groin site was also inspected by the attending radiologist after 4 hours and before discharge. Complications were noted in the form of groin hematoma, continuing bleeding from the puncture site, hypotension (defined as a fall in the systolic blood pressure of !20 mm Hg from the preprocedure blood pressure measurement), the need for intravenous fluids, and the requirement for surgery for incessant bleeding. If a groin complication developed, then the nursing personnel notified the interventionist to assess the patient. The patients were followed up at 24 hours after the procedure by telephone interview by the nurse who had attended the patient. The questions specifically addressed pain scores, whether there had been bleeding after discharge, and whether there was swelling or bruising at the puncture site. Pain was scored according to a standard scale, which ranged from 0 (no pain) to 10 (severe pain). All data were entered onto a predetermined questionnaire. Data were analysed by using frequency distributions and measures of central tendency.
Results

Deployment of Device
The device was used to achieve hemostasis at 84 femoral arterial puncture sites in 81 patients. The main results related to their hospital stay in the radiology recovery area are shown in Table 1 . From the figures, it can be deduced that the device was easy to deploy, with a total mean deployment time (including those cases in which it had to be reapplied) of just over 1 minute. Hemostasis was immediate and complete at 68 puncture sites (81%) after the first deployment. In 16 cases (19%), the device had to be reapplied because of inadequate hemostasis. In 5 patients (6%), the device had to be redeployed for the second time. Initial hemostasis was achieved in all 81 patients, with a mean total deployment time of 14.2 minutes. This included the time to initially deploy the device, the initial compression, and, finally, the time taken to fully release the pressure. It is important to note that, although in 9 patients there was a hematoma noted at discharge, in 8 of these cases, it was present before clamp deployment.
Complications Related to CompressAR StrongArm Device
Hematoma at 1 hour was seen in 20 patients and in only 9 patients at 4 hours. These were all minor hematomas (ie, <5 cm) that dissipated during the patient's recovery. Fortyfive patients were hypotensive at some point in the first 4 hours after the procedure, but only 10 patients were administered intravenous fluids. Of these, 4 were administered intravenous fluids as a precaution because of pre-existing renal failure. The remaining 6 patients were given fluids because of sustained hypotension (!15 minutes). In 5 of these patients, it was thought that this was probably because of a vasovagal response rather than a true reduction in venous return, because both bleeding and the presence of a false aneurysm were excluded by bed-side ultrasound examination. Only 1 patient required further imaging in the form of computed tomographic (CT) angiography because of continued ooze from the puncture site at 4 hours. In this case, there was no identifiable cause for the failure of the compression device because the procedure was straightforward. The patient had an enlarging hematoma and reduced blood pressure after the procedure. Subsequent CT angiography showed some active bleeding, which was managed conservatively. The patient was discharged home on the following day. No patient required further intervention in the form of transfusion or surgical repair.
The findings of the telephone interview undertaken at 24 hours are displayed in Table 2 . All discharged patients stated that they were comfortable at this time. No discharged patient experienced a rebleed from the puncture site or major hematoma within the first 24 hours.
All 10 patients who reported groin swelling the day after the procedure stated that these were small (<3 cm). These included the 9 patients who reported a hematoma within 24 hours of discharge (after leaving the hospital). The incidence of risk factors predisposing to bleeding in this patient group (obesity, hypertension, repeated puncture, vessel calcification, and long intake of anti-aggregation drugs) are shown in Table 3 . All patients were followed up at 6 months via a telephone call, and none were readmitted as a consequence of groin-related complications. 
Patient Comfort Related to Device Deployment
Pain scores at the time of sheath removal, 1 hour, 4 hours, and 24 hours are shown in Table 4 . The individual pain scores at 24 hours are shown in Figure 3 . Most patients reported no pain at all.
Discussion
Sheath removal is a routine part of nursing and physician practice after transfemoral catheterization and angioplasty. Although a recent North American survey noted that, in twothirds of hospitals, nurses removed sheaths without physician supervision [2] , at our institution, this is currently a timeconsuming process undertaken by the attending vascular interventionist.
The traditional method for sheath removal is manual compression on the puncture site, but this has gradually changed over time, with the development of various mechanical and invasive methods applied to the arteriotomy site. It was found that, in 39% of the hospitals surveyed in a North American study, pressure devices were being used ''frequently'' to achieve hemostasis after arterial punctures [2] .
Several studies have shown support for the use of the earlier standard CompressAR device after sheath removal in femoral punctures. A large multicentre study that compared manual compression with the CompressAR to achieve hemostasis, found that mechanical compression by using the CompressAR was less time consuming and was associated with a lower incidence of hematoma [3] . Other investigators concluded that the CompressAR was equally effective to manual compression but was more time consuming [4, 5] . A recent meta-analysis on the effectiveness of mechanical compression devices in attaining hemostasis after femoral sheath removal indicates that mechanical pressure is more effective than manual compression in preventing hematoma formation [6] .
There are currently no data assessing the CompressAR StrongArm device in day-case patients undergoing transfemoral peripheral angioplasty procedures. In this audit, the use of the system was associated with low access-site complication rates and ensured safe postcatheterization femoral hemostasis. Effective hemostasis was achieved in 80 of 81 patients (99%), with only 1 requiring further imaging for bleeding (CT angiogram) and subsequent admission. No patients required surgery.
At first glance, the hematoma rate at 24 hours of 11.9% appears high but it must be borne in mind that, of these, 9 , hypertension  3  None  4  None  5 Obesity, hypertension, aspirin 6 Aspirin 7
Obesity, hypertension 8 None 9
None 10 None Table 4 Pain scoring data assessed at the time of deployment up to 24 hours after the procedure were present before the deployment of the device. Several risk factors are known to influence the incidence of postcompression complications (Table 3) . It is clear from the data that the incidence of these factors cannot be said to have influenced the compression outcome. Only half of the 10 patients who reported hematoma at 24 hours reported at least 1 of these risk factors. The other 5 reported no such risk factors.
Pseudoaneurysm is a serious vascular complication that is usually difficult to recognize, especially in the presence of a hematoma [7] . It was previously suggested that the prevalence of pseudoaneurysm formation is significantly higher when manual compression is used to ensure hemostasis [8] .
Although clearly our audit is not a randomized study, none of the patients in the sample developed a subsequent pseudoaneurysm. There are no conclusive randomized trials that compared the rates of arteriovenous fistula formation or incidence local venous or arterial thromboses between mechanical pressure devices and manual compression. We report that none of these complications were seen in our treatment group.
Pain scores reported by patients were low, and so hemostatic efficacy was not at the detriment of patient comfort. With regard to a comparison in patient comfort between the use of the CompressAR StrongArm and manual compression, we have anecdotal evidence from 3 patients in our series who, on a previous occasion, had manual compression after angioplasty. They all stated that they preferred the CompressAR, but we have no direct comparison.
Another advantage was that the use of the device eliminated the need for manually compressing the femoral artery and allowed hands-free mechanical compression. This not only minimized exposure to blood during the hemostasis period but also increased nurse and physician productivity. The fact that our nursing staff had their ''hands free'' allowed them to chart observations and give medications. It is convention for the intervening radiologist to apply manual pressure after the procedure. The use of the CompressAR device placed the responsibility of monitoring the puncture site with the nursing staff once the device was used, and, in practical terms, this undoubtedly provided a time advantage over the traditional manual compression method.
Utilisation of the CompressAR StrongArm allowed hemostasis to be achieved with a minimum of effort and without the variable pressure that is unavoidable when the pressure is by hand. There is a tendency to ''peek'' when using one's hands to maintain pressure to see if hemostasis has occurred, which can predispose to hematoma formation [3] . Because staff avoid having to use manual compression, the risks of injury caused by repetitive motion are reduced. As well as its repetitive nature, manual compression is associated with the requirement of significant force, poor posture, severe hand fatigue, tendonitis, and carpal tunnel syndrome [9] .
We believe that this device offers advantages over older compression devices. For example, the Femostop relies on hydraulic pressure exceeding systemic pressure, so that, as the patient's blood pressure comes down, it exerts a higher pressure against the arterial wall. This can lead to arterial thrombosis and ischemia of the lower extremity. There have been reported iliac femoral grafts closing because of this complication. This has not yet been associated with use of the CompressAR.
The use of vascular closure devices certainly seems to have taken off over the last few years. However, in terms of hemostasis, the benefit of these devices over manual compression methods is contentious, and several investigators cited the lack of randomized long-term clinical trials in demonstrating a clear advantage for the use of vascular closure devices [10] . In fact, recent commentators concluded that, after cardiac catheterization, there is no advantage in using vascular closure devices, because early ambulation can be achieved with manual compression methods, which are inherently more economical [11] . Vascular closure devices are relatively expensive and are more than 20% of the cost of the CompressAR, with the only consumable cost being the disc. In addition, in a systematic review and meta-analysis of 30 trials that compared arterial puncture closing devices with standard manual compression after cardiac catheterization, Koreny et al [12] found that there is only marginal evidence that closure devices are effective, and they express concern that these devices may increase the risk of hematoma and pseudoaneurysm.
Infection, embolic, and vascular thrombotic complications associated with the use of vascular closure devices to achieve femoral hemostasis are uncommon but are serious complications associated with a high morbidity, which necessitates a need for aggressive intervention to salvage the situation [13] . These risks can also be minimized with mechanical compression.
Based on the results of this small study, it appears that the CompressAR StrongArm is an ideal hemostatic device in patients undergoing day-case interventional procedures and offers a low level of patient discomfort. It is user friendly, simple, and inexpensive, and provides rapid, reliable hemostasis. It is safe and likely to become a suitable alternative to other more-invasive closure devices.
Limitations of this audit include its small sample size and the fact that this was not a randomized study. Randomized controlled studies with larger sample populations that compare different methods of achieving hemostasis (manual compression, mechanical compression and closure device) are needed to ensure a more accurate data set that can be applied to the patient population.
